Meditech Formula 9 Injection Recalled for Sterility Assurance Issues
Meditech Laboratories is recalling Formula 9 Injection vials due to incomplete production data regarding sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. The hazard involves a lack of sterility assurance for an injectable drug, which poses a significant risk of serious injury or infection, meeting the criteria for a Severe rating.
Plain-English summary
Meditech Laboratories, Inc. is recalling 1,320 vials of Formula 9 Injection (Papaverine 0.9 mg, Phentolamine 0.1 mg, Atropine 0.01 mg, PGE 20 mcg/mL). The product is a prescription-only medication distributed nationwide. The specific lot number is 022416-9, with an expiration date of 04/09/16.
The recall was initiated due to a lack of assurance of sterility. The source text indicates that there is incomplete or missing data regarding the production process, which prevents verification that the product is sterile.
Consumers and healthcare providers should stop using the affected vials and contact Meditech Laboratories or their healthcare provider for further instructions on disposal or replacement.
The recalled product
- Product
- Formula 9 (Papaverine 0.9 mg, Phentolamine 0.1 mg, Atropine 0.01 mg, PGE 20 mcg/mL) Injection, 5 mL vial, Rx only, Meditech Laboratories, Inc., 3200 Polaris Ave., Suite 27, Las Vegas, NV 89102.
- Manufacturer
- Meditech Laboratories, Inc
- Category
- Drug — Injectable
- Hazard
- Affected units
- 1,320
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 022416-9
- Exp 04/09/16.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 7 recalled by Meditech Laboratories, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Meditech Laboratories, Inc
See all →- ModerateMeditech Formula 1 Injection Recalled Due to Expired Active Ingredient
FDA (Drugs) · 2016-04-13
- SevereMeditech Formula 0 Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2016-04-13
- SevereMeditech Formula 4 Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2016-04-13
- ModerateMeditech Formula 3 Injection Recalled Due to Expired Active Ingredient
FDA (Drugs) · 2016-04-13
- SevereMeditech Formula 2 Injection Recalled for Superpotent Drug Ingredient
FDA (Drugs) · 2016-04-13
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- HighCompounded Injectable Medication Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2022-06-01
- SevereVitalab Pharmacy Recalls Sterile Injectable Drug Due to Sterility Concerns
FDA (Drugs) · 2018-05-16
- SevereLiberty Drug Recalls Injectable Due to Sterility Process Deficiencies
FDA (Drugs) · 2015-09-02
- HighInjectable Papaverine/Phentolamine Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- HighFDA Recalls Papaverine/Phentolamine Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2023-02-01
- SevereLiberty Drug Recalls Papaverine Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-09-02